bioMerieux: H1 earnings up 23%
(CercleFinance.com) - bioMerieux has published H1 2020 net income, group share that is up 23% at 173 million euros, a 28% robust growth in contributive operating income before non-recurring items, to 253 million euros, or 17.
1% of sales.
The in vitro diagnostic specialist's H1 sales reached 1,476 million euros, with reported growth of 15.8% and organic growth of 15.7%, particularly boosted by clinical applications in molecular biology (+68.7%).
Alexandre Mérieux, Chairman and Chief Executive Officer, said, "Despite the pandemic's negative impact on certain product lines and taking into account health and economic conditions, bioMérieux is expected to deliver a remarkable performance this year. However, this performance is not projectable beyond 2020".
Copyright (c) 2020 CercleFinance.com. All rights reserved.
1% of sales.
The in vitro diagnostic specialist's H1 sales reached 1,476 million euros, with reported growth of 15.8% and organic growth of 15.7%, particularly boosted by clinical applications in molecular biology (+68.7%).
Alexandre Mérieux, Chairman and Chief Executive Officer, said, "Despite the pandemic's negative impact on certain product lines and taking into account health and economic conditions, bioMérieux is expected to deliver a remarkable performance this year. However, this performance is not projectable beyond 2020".
Copyright (c) 2020 CercleFinance.com. All rights reserved.